0000891293-16-000113.txt : 20160304
0000891293-16-000113.hdr.sgml : 20160304
20160304183033
ACCESSION NUMBER: 0000891293-16-000113
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160304
FILED AS OF DATE: 20160304
DATE AS OF CHANGE: 20160304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Plunkett Matthew
CENTRAL INDEX KEY: 0001557551
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12465
FILM NUMBER: 161486531
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE, SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2016-03-04
0
0000891293
CTI BIOPHARMA CORP
ctic
0001557551
Plunkett Matthew
3101 WESTERN AVENUE, SUITE 600
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Business Officer
Common Stock
2016-03-04
4
S
0
1300
0.585
D
598784
D
Common Stock
2016-03-04
4
S
0
400
0.586
D
598384
D
Common Stock
2016-03-04
4
S
0
636
0.587
D
597748
D
Common Stock
2016-03-04
4
S
0
1500
0.588
D
596248
D
Common Stock
2016-03-04
4
S
0
844
0.589
D
595404
D
Common Stock
2016-03-04
4
S
0
700
0.59
D
594704
D
Common Stock
2016-03-04
4
S
0
700
0.591
D
594004
D
Common Stock
2016-03-04
4
S
0
200
0.592
D
593804
D
Common Stock
2016-03-04
4
S
0
1100
0.593
D
592704
D
Common Stock
2016-03-04
4
S
0
500
0.594
D
592204
D
Common Stock
2016-03-04
4
S
0
1220
0.595
D
590984
D
Common Stock
2016-03-04
4
S
0
900
0.596
D
590084
D
The sale was effected pursuant to a Rule 10b5-1 trading plan.
By: Louis A. Bianco, Attorney-in-fact For: Matthew J. Plunkett
2016-03-04